Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of BI 1356 BS (Linagliptin) in Combination With Metformin in Patients With type2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion criteria:~Inclusion_Criteria:~* Male and female patients with a diagnosis of type 2 diabetes mellitus and previo usly treated with metformin alone or with metformin and one other oral antidiabetic d rug~* HbA1c 7.0 9.0% at screening for patients treated with metformin and one other oral antidiabetic drug~* HbA1c 7.5 10.0% at screening for patients treated with metformin alone~* HbA1c 7.5 10.0% at beginning of the placebo run-in phase~* Age \> 21 and \< 75 years~* MI \> 25 and \< 40 kg/m2 (Body Mass Index)~Exclusion criteria:~Exclusion_Criteria:~* Clinically relevant cardiovascular disease~* Impaired hepatic function~* Renal insufficiency or impaired renal function~* Treatment with rosiglitazone or pioglitazone within 6 months prior to screening~* Treatment with insulin within 3 months prior to screening

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Linagliptin low dose (Type: EXPERIMENTAL): Patients receive Linagliptin low dose tablets once daily
- Linagliptin medium dose (Type: EXPERIMENTAL): Patients receive Linagliptin medium dose tablets once daily
- Linagliptin high dose (Type: EXPERIMENTAL): Patients receive Linagliptin high dose tablets once daily
- Placebo (Type: PLACEBO_COMPARATOR): Patients receive tablets identical to those containing Linagliptin low, medium and high dose
- Glimepiride (Type: ACTIVE_COMPARATOR): Patients receive Glimepiride tablets once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).